Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2009. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction.
- Transaction Price: $29.58 per ADR
- Transaction Type: Increase in interest via dividend re-investment
- Dividend Date: April 9, 2009
Material Changes
The filing reports an increase in the Ordinary share ADR interest of Mr. D J Phelan. The total interest following the transaction is 289.51 shares. No other material financial changes or operational updates are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Verify the total shareholding of Mr. D J Phelan in subsequent filings to confirm the 289.51 ADR count.
- Confirm the dividend re-investment mechanism details for the April 9, 2009 payment.
- Note that this filing does not contain quarterly or annual financial performance data.